Toyama Chemical Launches Phase I Clinical Trials of Anti-rheumatic Agent T-5224.Tokyo, Japan, June 23, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Toyama Chemical has commenced phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of T-5224, its proprietary drug candidate for the treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. (RA). A low-molecular compound that inhibits an activator activator /ac·ti·va·tor/ (ak´ti-va?ter) 1. a substance that combines with an enzyme to increase its catalytic activity. 2. a substance that stimulates the development of a specific structure in the embryo. protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA. The development of T-5224 has been sponsored by the Japan Science and Technology Agency. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion